Immunome (IMNM) EBITDA margin US GAAP (year values) |
||||||||
2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
EBITDA margin, % | ? | -201.7% | -1 183% | |||||
Changes by years, y/y, % |
Immunome. EBITDA margin, %
Immunome. EBITDA margin, changes, pp
Immunome (IMNM) EBITDA margin US GAAP (quarter values) |
||||||||
2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
EBITDA margin, % | ? | -126.8% | -358.1% | -1 962% | -1 500% | -1 736% | -1 183% | |
Changes by years, y/y, % | -1 773pp | -1 368pp | -1 609pp | |||||
Changes by quarters, q/q, % | +5pp | -231pp | -1 604pp | +462pp | -237pp |